Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting session on understanding the current scenario of blood cancer. Genomic testing and advancements in diagnosis and treatment have revolutionized the field, moving beyond traditional methods to embrace a new era of personalized medicine. Comprehensive molecular profiling, often through Next-Generation Sequencing (NGS), is now a cornerstone of modern hematology. It allows clinicians to identify the specific genetic alterations and mutations that drive an individual's blood cancer, enabling more precise and effective diagnostic classifications and prognoses. This detailed genomic information is critical for guiding treatment decisions and selecting the most appropriate therapeutic strategies.
Building on these genomic insights, there have been remarkable advancements in treatment modalities. Targeted therapies, which are designed to block the proteins or pathways that mutated genes use to promote cancer growth, have emerged as a powerful alternative to conventional chemotherapy. In addition, cutting-edge immunotherapies like CAR T-cell therapy and bispecific antibodies are harnessing the body's own immune system to recognize and destroy cancer cells with unprecedented precision. These new therapies are not only showing better efficacy in many cases but are also associated with more manageable side effect profiles, significantly improving patients' quality of life.
Therefore, get an overall knowledge on the further discussion of the current scenario of blood cancer, with a focus on genomic testing and the latest advancements in diagnosis and treatment. Listen to the insights shared by Dr. Abhay Bhave, absorb the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation